BioMarin Pharmaceutical Inc. is a global rare disease biotechnology company focused on developing and commercializing medicines for genetically defined conditions. Founded in 1997, the company operates a portfolio of commercial therapies and a clinical pipeline targeting lysosomal storage disorders, metabolic conditions, and skeletal dysplasias. Key commercial products include VOXZOGO for achondroplasia, VIMIZIM for mucopolysaccharidosis IVA, NAGLAZYME for mucopolysaccharidosis VI, PALYNZIQ and KUVAN for phenylketonuria, ALDURAZYME for mucopolysaccharidosis I, and BRINEURA for neuronal ceroid lipofuscinosis type 2. The company also markets ROCTAVIAN for severe hemophilia A, though it has announced plans to withdraw this product from the market. BioMarin serves patients in the United States, the European Union, Japan, Australia, Brazil, and other international markets. Recent strategic moves include the acquisition of Inozyme Pharma to add a late-stage enzyme replacement therapy for ENPP1 deficiency and the pending acquisition of Amicus Therapeutics to expand its portfolio with treatments for Fabry disease and late-onset Pompe disease.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage biomarin.com
Sector Healthcare IR page investors.biomarin.com/overview/default.aspx
Tags
rare diseases, lysosomal storage disorders, enzyme replacement therapy, gene therapy, genetic conditions, achondroplasia, phenylketonuria, hemophilia, skeletal dysplasia, metabolic disorders, VOXZOGO, VIMIZIM, NAGLAZYME, PALYNZIQ, ALDURAZYME, BRINEURA, KUVAN, ROCTAVIAN, BMN 401, Inozyme Pharma, Amicus Therapeutics, BioMarin Europe Ltd., RareConnections
Press page biomarin.com/news/press-releases

Metrics

Valuation  
Market cap $ 11.621B
Market cap (USD) $ 11.621B
P/E -750.00
PEG —
P/BV 1.86
P/S 3.18
P/OCF 17.17
P/FCF 20.83
Dividend yield —
Turnover / mcap —
Returns  
ROE 5.9%
ROI 5.2%
ROIC 4.4%
Profit margin 10.8%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 35.1%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 66.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 56
Quality score -5.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001
Revenue 3.221B 2.854B 2.419B 2.096B 1.846B 1.86B 1.704B 1.491B 1.314B 1.117B 889.895M 751.04M 548.485M 500.723M 441.358M 376.267M 324.656M 296.493M 121.581M 84.209M 25.669M 18.641M — 13.919M —
Net profit 348.901M 426.859M 167.645M 141.561M -64.08M 859.1M -23.848M -77.211M -117.042M -630.21M -171.799M -133.969M -176.353M -114.347M -53.836M 205.819M -488K 30.831M -15.803M -28.533M -74.27M -187.443M -75.798M — —
Free cash flow 724.956M 487.417M 62.568M 54.943M 208.958M -28.947M -96.764M -124.412M -207.976M -376.217M -449.342M -192.373M -124.758M -26.962M -54.466M -30.715M -2.069M -65.543M -56.908M -74.673M -65.637M -89.216M -80.773M — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001
Share price 59.43 65.73 96.42 103.49 88.35 87.69 84.55 85.15 89.17 82.84 104.76 90.4 70.34 49.2 34.39 26.99 18.83 17.57 36.12 16.3 10.79 — — — —
Price performance 12m -0.1 -0.32 -0.07 0.17 0.01 0.04 -0.01 -0.05 0.08 -0.21 0.16 0.29 0.43 0.43 0.27 0.43 0.07 -0.51 1.22 0.51 — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 215M 261M 343M 377M 448M 373M 461M 634M 661M 908M
↳ YoY growth +30.5% +21.4% +31.1% +10.1% +18.8% -16.7% +23.5% +37.4% +4.2% +37.5%
↳ 5y CAGR +15.5% +19.1% +23.8% +21.2% +22.1% +11.6% +12.0% +13.1% +11.8% +15.2%
Borrowings, current (USD) — — — — — — — — — 0.00
Borrowings, non-current (USD) — — — — — — — — — 597M
Lease liabilities (USD) — — — 61.5M 56.2M 44.3M 36.9M 46.9M 38.8M 45.7M
Cash and deposits (USD) 408M 598M 494M 437M 649M 587M 725M 755M 943M 1.31B
Intangible assets (USD) 554M 518M 492M 457M 417M 389M 339M 295M 255M 214M
Right-of-use assets (USD) — — — 49M 46M 38.2M 34.9M 42.7M 28.7M 35.2M
Net debt (borrowings + leases - cash) (USD) — — — — — — — — — -715M
Cash flow detail
Operating cash flow (USD) -228M -8.76M 20.2M 48.3M 85.4M 305M 176M 159M 573M 828M
Purchases of property, plant and equipment (USD) -148M -199M -145M -145M -114M -95.6M -121M -96.7M -85.4M -103M
Purchases of intangible assets (USD) — 0.00 0.00 -18.4M -23.2M -23.6M -10.6M -10.9M -12M -7.94M
Change in receivables (cash effect) (USD) -51.5M -25.3M -54.3M -37.9M -59M 65.6M -82M -190M -57.9M -228M
Change in inventories (cash effect) (USD) -64.5M -96.9M -23.7M -108M -61.2M -35.1M -68.3M -157M -63.5M -117M
Change in payables (cash effect) (USD) -53.2M 45.5M 38.4M 77.1M -87M 15.7M 59M 68.9M -32.2M 66.1M
Share buybacks (cash effect) (USD) — — 0.00 0.00 -50M 0.00 0.00 — — —
Interest paid (cash effect) (USD) -8.64M -8.54M -11.6M -8.55M -12.2M -10.4M -10.3M -10.3M -10.4M -7.25M
Income taxes paid (cash effect) (USD) -95.9M -23.9M -16.7M -9.73M -8.98M -18.2M -54.4M -73.3M -57.3M -96.2M
Share-based compensation (USD) 135M 140M 149M 160M 190M 197M 196M 207M 202M 181M
Operating cash flow before change in receivables (USD) -176M 16.5M 74.5M 86.1M 144M 239M 258M 350M 631M 1.06B
Free cash flow (OCF - PPE - intangibles) (USD) -376M -208M -124M -115M -52.2M 185M 44.4M 51.6M 475M 717M
Income detail
Research and development expense (USD) 662M 611M 696M 715M 628M 629M 650M 747M 747M 922M
↳ 5y CAGR +25.3% +15.1% +14.4% +9.1% -0.2% -1.0% +1.2% +1.4% +0.9% +8.0%
Total comprehensive income (USD) -638M -153M -48.4M -8.96M 823M -33.5M 123M 143M 517M 274M
Comprehensive income to owners (USD) -638M -153M -48.4M -8.96M 823M -33.5M 123M 143M 517M 274M
Reported Feb 27, 2017 Feb 27, 2020 Feb 26, 2021 Feb 26, 2021 Feb 26, 2021 Feb 25, 2022 Feb 27, 2023 Feb 26, 2024 Feb 24, 2025 Aug 6, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 4, 2026

  • Stifel Healthcare Conference, November 11 at 3:20 pm EST
  • UBS Global Biopharma Conference, November 16 at 9:20 am GMT
  • Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT

SAN RAFAEL, Calif., Nov. 4, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in November.

BioMarin Pharmaceutical logo

An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/ . An archived version of the remarks will also be available through the Company's website for a limited time following the conference. 

**About BioMarin
**BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com .

Contacts:
Investors Media
Traci McCarty Marni Kottle
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 455-7558 (650) 374-2803

SOURCE BioMarin Pharmaceutical Inc.

Stay updated.

Subscribe to our email alerts for investors to stay informed about the latest developments at BioMarin.

Subscribe

You’re leaving the BioMarin website.

Links to sites outside of this website are provided as a resource to the viewer. BioMarin accepts no responsibility for the content of linked sites.

Leave this website Close

Enter your DIN number

Please locate the 8-digit DIN number found on your product package or educational materials and enter it in the form below to access important safety information.

DIN number

Biomarin

Contact
Legal

© 2026 BioMarin. All rights reserved.

News Details Bull 0 Bear 0 Routine

View All News

BioMarin to Participate in Upcoming Investor Conferences

November 4, 2026

  • Stifel Healthcare Conference, November 11 at 3:20 pm EST
  • UBS Global Biopharma Conference, November 16 at 9:20 am GMT
  • Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT

SAN RAFAEL, Calif., Nov. 4, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in November.

BioMarin Pharmaceutical logo

An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/ . An archived version of the remarks will also be available through the Company's website for a limited time following the conference. 

**About BioMarin
**BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com .

Contacts:
Investors Media
Traci McCarty Marni Kottle
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 455-7558 (650) 374-2803

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-participate-in-upcoming-investor-conferences-302928633.html

SOURCE BioMarin Pharmaceutical Inc.

View All News

Traci McCarty Marni Kottle Bull 4 Bear 3 Results

BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.

(415) 455-7558 (650) 374-2803

BioMarin Reports Third Quarter 2026 Financial and Operating Results

Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y

Updates Full-year 2026 Guidance to Reflect Order Timing Uncertainty and Impact of Two Acquired In-process Research and Development (IPR&D) Charges

Recently Announced the Addition of a New Investigational Fabry Asset to Clinical Portfolio

PDUFA Action Date of May 30, 2027 for VOXZOGO® for the Treatment of Hypochondroplasia (HCH)

Conference Call and Webcast Scheduled Today at 4:30 p.m. ET

SAN RAFAEL, Calif., November 2, 2026 – BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the third quarter ended September 30, 2026.

“BioMarin delivered a strong quarter, with revenue growth of 32%, driven by a more diversified portfolio following the acquisition of Amicus Therapeutics earlier this year and increased demand for our medicines from patients around the world.

Prompts

BioMarin Pharmaceutical Inc. (ticker BMRN), listed in United States.

ETFs Holding BioMarin Pharmaceutical Inc.

ETF Weight in ETF Shares Market value As of
CGVV 1.59% 55,794 $ 3.235M Nov 16, 2026
RNIN 1.12% 40,190 $ 2.35M Nov 18, 2026
BMED 1.03% 2,533 $ 146.889K Nov 16, 2026
LSEQ 0.70% 2,140 $ 122.472K Nov 13, 2026
AFMC 0.65% 29,648 $ 1.719M Nov 16, 2026
FEMV 0.62% 576 $ 32.959K Jun 30, 2026
LCF 0.58% 6,594 $ 377.309K Jun 30, 2026
SYZ 0.52% 6,190 $ 354.192K Jun 30, 2026
ABCS 0.49% 948 $ 61.838K Aug 31, 2026
REGS 0.46% 5,195 $ 297.258K Jun 30, 2026
MKTN 0.35% 6,569 $ 375.878K Jun 30, 2026
DSTL 0.32% 118,526 $ 6.782M Jun 30, 2026
DFSV 0.31% 1,514,423 $ 85.868M Nov 12, 2026
ITAN 0.31% 6,515 $ 381.193K Nov 17, 2026
JMEE 0.23% 109,956 $ 6.434M Nov 17, 2026
FMDE 0.21% 267,272 $ 15.293M Jun 30, 2026
DFAS 0.15% 873,558 $ 49.531M Nov 12, 2026
VFVA 0.14% 20,990 $ 1.369M Aug 31, 2026
AVMC 0.12% 11,582 $ 671.64K Nov 16, 2026
FELV 0.11% 60,231 $ 3.446M Jun 30, 2026
FYEE 0.11% 3,901 $ 234.138K Jul 31, 2026
AVIE 0.10% 291 $ 16.875K Nov 16, 2026
REMC 0.08% 45 $ 2,574.90 Jun 30, 2026
FEAC 0.07% 300 $ 17.166K Jun 30, 2026
DFAT 0.05% 281,897 $ 15.984M Nov 12, 2026
JUSA 0.05% 6,759 $ 395.469K Nov 17, 2026
DFSU 0.04% 18,951 $ 1.075M Nov 12, 2026
DFAC 0.04% 642,049 $ 36.404M Nov 12, 2026
DXUV 0.03% 38,447 $ 2.18M Nov 12, 2026
AVSU 0.03% 2,479 $ 143.757K Nov 16, 2026
IALT 0.03% 40,551 $ 2.352M Nov 16, 2026
AVLC 0.03% 7,528 $ 436.549K Nov 16, 2026
FHEQ 0.02% 3,375 $ 202.568K Jul 31, 2026
VSLU 0.02% 1,941 $ 111.064K Jun 30, 2026
AVUS 0.02% 45,482 $ 2.638M Nov 16, 2026
JSTC 0.02% 1,106 $ 64.137K Nov 17, 2026
DFAU 0.02% 45,462 $ 2.578M Nov 12, 2026
DCOR 0.02% 156,349 $ 8.865M Nov 12, 2026
DFUS 0.01% 55,558 $ 3.15M Nov 12, 2026
DFUV 0.01% 25,505 $ 1.446M Nov 12, 2026
EBI 0.00% 272 $ 17.743K Aug 31, 2026
DFLV 0.00% 1,028 $ 58.288K Nov 12, 2026